NCT02227251Phase 2Active not recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants244Estimated

Source updated2026-07-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-06 · 2 fields changed

Primary completion date

Recorded edit

− Previous value

2027-04

+ Updated value

2026-12

Recruitment status

Recorded edit

− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source

Study details

Conditions studied

Diffuse Large B-cell Lymphoma

Treatments or interventions studied

SelinexorDrugAlso known as KPT-330
SelinexorDrugAlso known as KPT-330
SelinexorDrugAlso known as KPT-330

Primary outcomes · main study measures

Read the study measures

measure: Part 1: Overall Response Rate (ORR); description: Assessed according to the revised response criteria based on the Guidelines of the International Working Group (IWG).; timeFrame: One year; measure: Part 2: Overall Response Rate (ORR) Based on Lugano Criteria; description: Assessed according to the response assessment of lymphoma based on Lugano classification.; timeFrame: From initial randomization until date of disease progression or death (maximum of 1 year from Part 2 randomization)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history